News | October 25, 2025
Syngene International expands capabilities with new bioconjugation suite in Bengaluru
Bioconjugation capability to complement commercial payload, linker, and monoclonal antibody services
Bioconjugation capability to complement commercial payload, linker, and monoclonal antibody services
Overall investment in the US facility is estimated around US$50 million
New facility includes 20KL of single use drug substance capacity coupled with drug product filling capacity of up to one million vials per day
The quarter also saw continued investment in new technologies and the successful implementation of several digitization and automation projects across operations
Subscribe To Our Newsletter & Stay Updated
